Trial establishes the clinical utility of circulating tumor cell count as biomarker i

[News]

The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine therapy as first-line therapy for patients with metastatic, estrogen receptor (ER)-positive/HER2-negative breast cancer provided overall survival benefit, compared with physician's choice of treatment, according to data from the STIC CTC trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

More... (https://www.news-medical.net/news/20221208/Trial-establishes-the-clinical-utility-of-circulating-tumor-cell-count-as-biomarker-in-breast-cancer-care.aspx)